about
Imatinib mesylate in chordomaHigh-dose continuous-infusion ifosfamide in advanced well-differentiated/dedifferentiated liposarcomaClinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal TumorA phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.Proteomic detection of a large amount of SCGFα in the stroma of GISTs after imatinib therapy.Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST).Folate-related polymorphisms in gastrointestinal stromal tumours: susceptibility and correlation with tumour characteristics and clinical outcome.Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?Carney triad can be (rarely) associated with germline succinate dehydrogenase defects.Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis.Adjuvant therapy of gastrointestinal stromal tumors (GIST).Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup RandomiAre two better than one? A novel double-mutant KIT in GIST that responds to ImatinibStimulation of IL-12 secretion by GM-CSF in advanced cancer patients.Effect of bicalutamide therapy on prolactin response to L-dopa in metastatic prostate cancer patients.Activate and resist: L576P-KIT in GIST.Efficacy of monochemotherapy with docetaxel (taxotere) in relation to prolactin secretion in heavily pretreated metastatic breast cancer.Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy.Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Imatinib response in two GIST patients carrying two hitherto functionally uncharacterized PDGFRA mutations: an imaging, biochemical and molecular modeling study.Oncogenic and ligand-dependent activation of KIT/PDGFRA in surgical samples of imatinib-treated gastrointestinal stromal tumours (GISTs).Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.Genome-Wide Analysis Identifies MEN1 and MAX Mutations and a Neuroendocrine-Like Molecular Heterogeneity in Quadruple WT GIST.Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).Lung metastasectomy in adenoid cystic carcinoma (ACC) of salivary glandStimulation of IL-18 secretion by IL-2 in patients with advanced cancer
P50
Q28282621-176B8264-EFF7-4F86-A62A-69B1B8A3A034Q33420031-44E14D2C-2DF9-403B-A05F-B7872E40CE5BQ33420123-A0B38693-C8FD-4BDA-A7AE-C1B96909C46BQ33432047-E54A5E65-6734-4AC3-94AE-04C5216A172EQ33817421-AD9F98C0-63AC-4250-81DD-874941DB2D84Q34029127-4DDC27AC-8C69-42F4-BA68-876C471D6BA8Q34602457-2F85424B-70A7-4E3A-B350-EC0A9E9F7954Q36695209-62990CDC-22ED-47C7-92CB-D06BA831EB61Q36970527-9E136E54-9321-4732-AE22-C5885FEBC052Q37058010-07ECB2C9-7FBF-409F-A054-E7B18AE3571FQ37688382-A2CE45CA-838C-43B7-AF38-B9EE6A609B4FQ38022443-F9083262-3D9D-4334-8D2A-5FC1EB14CCFEQ40317214-97B09F1B-FEAA-44E2-89CB-F01D8227E96EQ41134178-0150D5A4-460C-4618-B4D2-F8394D6CA39BQ42508519-2C71BBFB-8454-40FF-9AE0-7AA082041DA2Q42518299-A2D74AC5-3776-489E-840D-16BAA8557987Q43282319-C85528A5-694D-45F8-A5AB-0466A064C599Q43596751-597C88DA-2538-4302-AFD5-A99206B5F3E8Q45180974-4B59D364-A289-4B7C-8629-7FAA49017C95Q45784297-B3355AA5-9ADC-4C3F-ABDF-90201F968F96Q46092027-C427B002-733C-47DF-AB0A-53B05BCA5DB4Q46273752-7AF6549A-8ECF-438F-8E33-2176C8EDF093Q50913835-C36B3EA3-F11C-471F-AE9F-A9DA44EBF273Q51694181-E55C10DF-D11E-4F28-8418-76870947F009Q52737237-B3A8C9C8-5783-471F-AE64-ADF3B689DC63Q53135694-4A21DB8A-6809-4DF8-97AC-C83BCDFCBB85Q60461762-60A55D8D-D1ED-42CC-AE55-DA6F2C6F2092Q60461770-4CA40700-EC51-4BBF-B260-6C4C3A389F5C
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Elena Fumagalli
@ast
Elena Fumagalli
@en
Elena Fumagalli
@es
Elena Fumagalli
@nl
Elena Fumagalli
@sl
type
label
Elena Fumagalli
@ast
Elena Fumagalli
@en
Elena Fumagalli
@es
Elena Fumagalli
@nl
Elena Fumagalli
@sl
prefLabel
Elena Fumagalli
@ast
Elena Fumagalli
@en
Elena Fumagalli
@es
Elena Fumagalli
@nl
Elena Fumagalli
@sl
P1053
E-2065-2017
P106
P1153
7004695354
P21
P31
P3829
P496
0000-0003-4814-7637